More than 100,000 bottles of a common over-the-counter pain reliever are being recalled across the United States after a labelling mix-up put the wrong product name on the bottle itself. The ValuHealth acetaminophen recall covers 100,134 bottles of Extra Strength Pain Relief Acetaminophen 500 mg caplets, and the detail that matters most is on the packaging: the outer carton is correct, but the label on the bottle inside names a different medicine. For anyone who keeps pain relief in a bathroom cabinet, a desk drawer or a car glovebox, that mismatch is exactly why regulators are urging a closer look before the next dose.
The recall, published in a U.S. Food and Drug Administration (FDA) enforcement notice, is nationwide. It applies to one lot, with one expiration date, distributed by Prodose, Inc., of New York, and manufactured in India. The FDA initiated the recall on October 14, 2026, and classified it as Class III on October 26, 2026, the agency's lowest-risk category, meaning adverse health consequences are not likely. That classification is reassuring, but it does not erase the reason for the recall: a consumer who trusts the bottle label alone could believe they are holding a different formulation from the one in the carton.
According to the FDA enforcement notice, the problem is a straightforward labelling discrepancy. The outer carton correctly identifies the product as ValuHealth Extra Strength Pain Relief Acetaminophen, a standard pain and fever reliever. The label attached to the individual bottle, however, identifies the contents as ValuHealth Extra Strength Pain Relief PM. Those are two different products that happen to share a brand, a strength of acetaminophen and a similar name.
Standard extra-strength acetaminophen is used to relieve mild to moderate pain and to reduce fever. The nighttime PM version adds a second active ingredient: 25 mg of diphenhydramine per caplet, alongside the same 500 mg of acetaminophen. Diphenhydramine is an antihistamine used for allergy symptoms and, in nighttime products, to help with occasional sleeplessness. It is also an ingredient found in certain products sold under the Benadryl brand. Because diphenhydramine can cause drowsiness, the distinction between the daytime and nighttime versions is not cosmetic. It changes how, and when, a medicine should be used, and which precautions apply.
The notice identifies the affected product precisely, and that precision is the point. Consumers are asked to compare the lot number and expiration date on their packaging with the recalled details, rather than relying on the product name alone. Checking the name alone is not sufficient here, because the recall exists precisely because the carton and the bottle disagree. The affected bottles are 40-count bottles of ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg caplets, lot P260252, expiring April 30, 2029, distributed nationwide by Prodose, Inc.
Acetaminophen is one of the most widely used over-the-counter medicines in the United States. It is sold under many brand and store names, it appears in combination cold, flu and sleep products, and it is easy to take without thinking twice about it. That familiarity is part of why labelling accuracy matters so much: people rely on the label printed directly on the bottle to identify ingredients, understand the intended use, check the dose and recognise warnings. When the bottle and the carton tell different stories, that chain of trust breaks down.
The FDA uses three recall classifications to describe the potential health risk of a recalled product. A Class I recall is the most serious, involving a reasonable probability of serious adverse health consequences or death. A Class II recall applies when exposure may cause temporary or medically reversible health consequences, or when the probability of serious consequences is remote. A Class III recall, the category applied here, applies when using or being exposed to a product is not likely to cause adverse health consequences. The agency's classification reflects its assessment of risk from the violation, not a guarantee that every possible use of the product is safe, and it does not mean a recall should be ignored.
This is also the second widely reported acetaminophen recall this month, although the two actions involve different products and different reasons. Earlier in October, an FDA notice described a recall affecting approximately 113,000 bottles of generic acetaminophen sold through Amazon after complaints about discoloration. That action involved bottles containing 200, 500 and 1,000 caplets, and its reported reason was the appearance of the tablets, not a labelling error. Consumers should not assume that all acetaminophen products are affected by either recall, and the reports do not indicate that Tylenol is subject to the ValuHealth recall. The ValuHealth action applies only to the specific product, lot and packaging details identified in the FDA notice.
The check takes less than a minute, and it should start with the bottle, not the box. First, look for the brand ValuHealth and the product name Extra Strength Pain Relief Acetaminophen 500 mg. Then compare the lot number, P260252, and the expiration date, April 30, 2029, against the bottle in your hand. If the bottle label instead reads Extra Strength Pain Relief PM, treat that as a red flag and do not rely on the outer carton alone to identify what you have.
Next, think about what else is in the medicine cabinet. Acetaminophen appears in many combination products, and taking more than the recommended amount can cause serious liver damage, particularly when several medicines containing acetaminophen are used together. A labelling error adds a second risk on top of that: a person who believes they are taking a plain daytime pain reliever might not expect drowsiness, while a person who believes they are taking a nighttime product might take it at the wrong time of day. Anyone who is uncertain about which formulation they actually have should ask a pharmacist or healthcare professional rather than guessing from the carton.
The FDA notice reviewed for this article provided no specific consumer instructions, such as a return or refund process, for people who find an affected bottle. As a precaution, consumers should verify the lot number, expiration date and labelling, consult the official FDA enforcement report or contact the distributor for clarification about the recall and any recommended next steps, and seek advice from a qualified healthcare professional if they have already taken the medication and are concerned. Anyone experiencing a serious or unexpected reaction should seek appropriate medical attention promptly.
No company statement or direct quote from Prodose, Inc. was included in the FDA notice material reviewed for this article, and no adverse-reaction reports were cited in that material. That absence is itself worth stating plainly: the public record for this recall, as published, rests on the FDA enforcement notice and its classification, not on a manufacturer explanation of how the wrong label reached the bottles.
The FDA's own framing is the clearest official signal available. By classifying the action as Class III, the agency indicated that adverse health consequences are not likely, while still publishing the recall so consumers can identify the affected lot. Regulators and pharmacists have long made the same broader point in labelling cases: accurate labels are essential for safe use, because labels are how consumers identify active ingredients, understand intended uses, review dosage instructions and recognise warnings. When a bottle label conflicts with its outer packaging, consumers may struggle to determine which formulation they possess, and that uncertainty is the harm the recall is designed to remove, even when the risk category is low.
Consumer advocates and pharmacists routinely advise the same practical steps in cases like this: read labels carefully, check active ingredients rather than brand names alone, follow dosage instructions, and ask a pharmacist when information appears inconsistent. Those steps matter most for nighttime products, because an ingredient that causes drowsiness changes whether a medicine is safe to take before driving, operating machinery or taking other sedating medicines. This article is for information only and is not medical advice; anyone unsure about a medicine they have taken should speak to a pharmacist or clinician.
At first glance, a Class III recall of a mislabelled pain reliever can look minor. No serious harm is expected, no dramatic symptoms are reported, and the medicine itself is familiar. The reason it still matters is that the error strikes at the one safeguard consumers actually use every day: the label. Prescription medicines pass through pharmacists and prescribers who can catch discrepancies. Over-the-counter medicines do not. The bottle label is often the only check between a shopper and a dose, and when that label names the wrong formulation, the safeguard fails silently.
The timing also matters. Acetaminophen is a medicine people reach for when they are already unwell, tired or in pain, which is exactly when careful label-reading is hardest. A daytime product mislabelled as a nighttime product, or a nighttime product mistaken for a daytime one, can lead to unexpected drowsiness at the wrong hour, or to a person unknowingly combining acetaminophen from several sources. The recall is therefore less about one lot of one brand and more about a reminder that applies to every bottle in the cabinet: check the active ingredients, check the lot, and do not assume two similar names mean two interchangeable medicines.
For the wider medicines market, the case is a reminder of how much depends on packaging and quality control before products reach store shelves. Manufacturers and distributors are responsible for ensuring products are packaged and labelled correctly, and regulators publish enforcement notices precisely so that a low-risk error does not stay hidden. Paying attention to those notices, even when the classification is low, is how small errors are caught before they become larger ones.
Consumers who find lot P260252 should set the bottle aside, verify the details against the FDA enforcement report, and contact the distributor or a pharmacist for clarification on next steps. The FDA enforcement report is updated as recalls progress, so the lot list and any return instructions should be checked against the official notice rather than social media summaries. No wider expansion of this recall has been announced in the material reviewed, and no other ValuHealth lot was identified as affected.
Regulators will also be watched for any follow-up: whether the labelling error is traced to a single production run, whether other lots or products from the same distributor are reviewed, and whether the manufacturer issues a public statement. For now, the practical advice stands unchanged. Check the bottle, check the lot, and if anything does not match, ask a pharmacist before taking another dose.
Which ValuHealth product is recalled? ValuHealth Extra Strength Pain Relief Acetaminophen 500 mg caplets, in 40-count bottles, lot P260252, expiring April 30, 2029, distributed nationwide by Prodose, Inc.
What is wrong with the recalled bottles? The outer carton correctly names acetaminophen, but the bottle label names the nighttime PM version, which also contains 25 mg of diphenhydramine per caplet.
Is this recall dangerous? The FDA classified it as Class III, meaning adverse health consequences are not likely. That does not mean it should be ignored; the labelling mismatch can still cause confusion about ingredients and drowsiness.
What should I do if I have an affected bottle? Verify the lot and expiration date, do not rely on the carton name alone, consult the FDA enforcement report or the distributor for next steps, and ask a pharmacist or healthcare professional if you are unsure or concerned.
Are all acetaminophen products recalled? No. This recall applies only to the specific ValuHealth lot identified above, and it is separate from the earlier Amazon acetaminophen recall over discolored tablets. Tylenol was not identified as subject to the ValuHealth recall.
Related coverage on US News Pulse: Taylor Farms salad recall over hidden allergens and FDA warning on Darwin's cat food after a cat was hospitalised.
Sources: FDA enforcement notice via Rejoy Health, October 28, 2026; FDA recall classification and product details as published in that notice; earlier Amazon acetaminophen recall reporting, October 2026. This article is for information only and is not medical advice.
Leave a Comment
| Today's Date:
